Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.

Cohen JA, Rossi FM, Zucchetto A, Bomben R, Terzi-di-Bergamo L, Rabe KG, Degan M, Steffan A, Polesel J, Santinelli E, Innocenti I, Cutrona G, D' Arena G, Pozzato G, Zaja F, Chiarenza A, Rossi D, Di Raimondo F, Laurenti L, Gentile M, Morabito F, Neri A, Ferrarini M, Fegan CD, Pepper CJ, Del Poeta G, Parikh SA, Kay NE, Gattei V.

Haematologica. 2019 Oct 3. pii: haematol.2019.228171. doi: 10.3324/haematol.2019.228171. [Epub ahead of print]

2.

Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggin A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, Patriarca A, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben R, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foá R, Gaidano G, Rossi D.

Haematologica. 2019 Aug 1. pii: haematol.2019.219550. doi: 10.3324/haematol.2019.219550. [Epub ahead of print]

3.

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Innocenti I, Morelli F, Autore F, Piciocchi A, Frustaci A, Mauro FR, Schiattone L, Trentin L, Del Poeta G, Reda G, Rigolin GM, Ibatici A, Ciolli S, Coscia M, Sportoletti P, Murru R, Levato L, Gentile M, D'Arena G, Efremov DG, Tedeschi A, Scarfò L, Cuneo A, Foà R, Laurenti L.

Br J Haematol. 2019 Oct;187(1):e8-e11. doi: 10.1111/bjh.16123. Epub 2019 Jul 31. No abstract available.

PMID:
31364153
4.

HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.

Griggio V, Vitale C, Todaro M, Riganti C, Kopecka J, Salvetti C, Bomben R, Dal Bo M, Magliulo D, Rossi D, Pozzato G, Bonello L, Marchetti M, Omedè P, Kodipad AA, Laurenti L, Del Poeta G, Mauro FR, Bernardi R, Zenz T, Gattei V, Gaidano G, Foà R, Massaia M, Boccadoro M, Coscia M.

Haematologica. 2019 Jul 9. pii: haematol.2019.217430. doi: 10.3324/haematol.2019.217430. [Epub ahead of print]

5.

Intravascular Colonization of Kaposi Sarcoma: Expanding the Spectrum of Specific Infiltrates of B-Cell Chronic Lymphocytic Leukemia.

Saggini A, Del Poeta G, Santinelli E, Bianchi L, Caposiena Caro RD, Orlandi A.

Am J Dermatopathol. 2019 Jun 27. doi: 10.1097/DAD.0000000000001481. [Epub ahead of print]

PMID:
31268930
6.

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival.

Vendramini E, Bomben R, Pozzo F, Benedetti D, Bittolo T, Rossi FM, Dal Bo M, Rabe KG, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Braggio E, Parikh SA, Kay NE, Shanafelt TD, Del Poeta G, Gattei V, Zucchetto A.

Leukemia. 2019 Aug;33(8):2111-2115. doi: 10.1038/s41375-019-0444-6. Epub 2019 Mar 14. No abstract available.

7.

Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome.

Del Principe MI, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A, Consalvo MI, Paterno G, Sarlo C, De Bellis E, Zizzari A, De Angelis G, Fraboni D, Divona M, Voso MT, Sconocchia G, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Semin Hematol. 2018 Oct;55(4):209-214. doi: 10.1053/j.seminhematol.2018.02.006. Epub 2018 Feb 21. Review.

PMID:
30502849
8.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
9.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Raponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R.

Br J Haematol. 2019 Apr;185(1):156-159. doi: 10.1111/bjh.15405. Epub 2018 May 22. No abstract available.

PMID:
29785734
10.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
11.

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.

Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A.

J Exp Med. 2018 Feb 5;215(2):681-697. doi: 10.1084/jem.20171288. Epub 2018 Jan 4.

12.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
13.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
14.

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Laurenti L, Innocenti I, Autore F, Ciolli S, Mauro FR, Mannina D, Del Poeta G, D'Arena G, Massaia M, Coscia M, Molica S, Pozzato G, Efremov DG, Vannata B, Marasca R, Galieni P, Cuneo A, Orlando S, Piciocchi A, Boncompagni R, Vincelli D, Liberati AM, Russo F, Foá R.

Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8. No abstract available.

15.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

16.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
17.

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.

Mauro FR, Galieni P, Tedeschi A, Laurenti L, Del Poeta G, Reda G, Motta M, Gozzetti A, Murru R, Caputo MD, Campanelli M, Frustaci AM, Innocenti I, Raponi S, Guarini A, Morabito F, Foà R, Gentile M.

Am J Hematol. 2017 Jun;92(6):529-535. doi: 10.1002/ajh.24714. Epub 2017 Apr 18.

18.

Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Picardi A, Cerretti R, Cudillo L, De Angelis G, Sarlo C, Cefalo M, Ditto C, Di Veroli A, Mariotti B, Nasso D, De Bellis E, Del Poeta G, Voso MT, Sconocchia G, Lo Coco F, Arcese W, Amadori S, Venditti A.

Bone Marrow Transplant. 2017 Mar;52(3):473-475. doi: 10.1038/bmt.2016.308. Epub 2016 Dec 12. No abstract available.

PMID:
27941782
19.

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, De Bellis E, Di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso MT, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052. eCollection 2016. Review.

20.

A case of SRSF2 mutation in chronic lymphocytic leukemia.

Garza E, Del Poeta G, Martínez-Losada C, Catalano G, Borgia L, Piredda ML, Fabiani E, Gattei V, Lo-Coco F, Noguera NI.

Leuk Res Rep. 2016 Jun 23;6:11-4. doi: 10.1016/j.lrr.2016.03.001. eCollection 2016.

21.

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.

Zucchetto A, Tissino E, Hartmann TN, Chigaev A, Del Poeta G, Colombatti A, Gattei V.

Clin Cancer Res. 2016 Jul 1;22(13):3410-1. doi: 10.1158/1078-0432.CCR-16-0050. No abstract available.

22.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Review.

PMID:
27252989
23.

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.

Dal Bo M, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, Tissino E, Benedetti D, Bittolo T, Nanni P, Cattarossi I, Zaina E, Chivilò H, Degan M, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Principe MI, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.

PMID:
27109509
24.

A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature.

Del Principe MI, Sarmati L, Cefalo M, Fontana C, De Santis G, Buccisano F, Maurillo L, De Bellis E, Postorino M, Sconocchia G, Del Poeta G, Sanguinetti M, Amadori S, Pagano L, Venditti A.

Mycoses. 2016 Sep;59(9):594-601. doi: 10.1111/myc.12508. Epub 2016 Apr 8. Review.

PMID:
27061932
25.

Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D, Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G.

Haematologica. 2016 Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854. Epub 2015 Nov 12.

26.

Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.

Laurenti L, Innocenti I, Autore F, Vannata B, Efremov DG, Ciolli S, Del Poeta G, Mauro FR, Cortelezzi A, Borza PA, Ghio F, Mondello P, Murru R, Gozzetti A, Cariccio MR, Piccirillo N, Boncompagni R, Cantonetti M, Principe MI, Reda G, Bongarzoni V, Cervetti G, Pitini V, Foà R, Sica S, D'Arena G.

Leuk Res. 2015 Oct;39(10):1066-70. doi: 10.1016/j.leukres.2015.07.009. Epub 2015 Jul 26.

PMID:
26307523
27.

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G.

Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.

28.

Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?

Benedetti D, Tissino E, Caldana C, Dal Bo M, Bomben R, Marconi D, Ganghammer S, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Del Poeta G, VanMeter A, Zucchetto A, Espina V, Liotta L, Gattei V.

Leukemia. 2016 Feb;30(2):513-7. doi: 10.1038/leu.2015.149. Epub 2015 Jun 19. No abstract available.

PMID:
26183532
29.

NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.

Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M.

Leukemia. 2016 Jan;30(1):182-9. doi: 10.1038/leu.2015.182. Epub 2015 Jul 13.

PMID:
26165233
30.

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.

Dal Bo M, D'Agaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D, Zaja F, Pozzato G, Di Raimondo F, Gaidano G, Laurenti L, Del Poeta G, Efremov DG, Gattei V, Bomben R.

Oncotarget. 2015 Aug 7;6(22):19102-17.

31.

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.

Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.

Ann Hematol. 2015 Aug;94(8):1319-26. doi: 10.1007/s00277-015-2364-5. Epub 2015 Apr 14.

PMID:
25869029
32.

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia.

Wang J, Khiabanian H, Rossi D, Fabbri G, Gattei V, Forconi F, Laurenti L, Marasca R, Del Poeta G, Foà R, Pasqualucci L, Gaidano G, Rabadan R.

Elife. 2014 Dec 11;3. doi: 10.7554/eLife.02869.

33.

Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.

Del Principe MI, Maurillo L, Buccisano F, Sconocchia G, Cefalo M, De Santis G, Di Veroli A, Ditto C, Nasso D, Postorino M, Refrigeri M, Attrotto C, Del Poeta G, Lo-Coco F, Amadori S, Venditti A.

Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014075. doi: 10.4084/MJHID.2014.075. eCollection 2014. Review.

34.

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia.

Dereani S, Macor P, D'Agaro T, Mezzaroba N, Dal-Bo M, Capolla S, Zucchetto A, Tissino E, Del Poeta G, Zorzet S, Gattei V, Bomben R.

J Hematol Oncol. 2014 Oct 23;7:79. doi: 10.1186/s13045-014-0079-z.

35.

Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.

Niscola P, Tendas A, Cupelli L, Giovannini M, Piccioni D, Scaramucci L, Dentamaro T, Del Poeta G, de Fabritiis P.

Acta Haematol. 2015;133(1):64-6. doi: 10.1159/000363643. Epub 2014 Aug 14. No abstract available.

PMID:
25139255
36.

Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.

Dal Bo M, Tissino E, Benedetti D, Caldana C, Bomben R, Del Poeta G, Gaidano G, Rossi FM, Zucchetto A, Gattei V.

Semin Hematol. 2014 Jul;51(3):168-76. doi: 10.1053/j.seminhematol.2014.05.002. Epub 2014 May 15. Review.

PMID:
25048781
37.

Extensive toxic epidermal necrolysis following brentuximab vedotin administration.

Del Principe MI, Sconocchia G, Buccisano F, Cefalo M, Di Veroli A, De Santis G, Nasso D, Maurillo L, Anemona L, Postorino M, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2015 Feb;94(2):355-6. doi: 10.1007/s00277-014-2148-3. Epub 2014 Jul 2. No abstract available.

PMID:
24981690
38.

NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.

Bo MD, Del Principe MI, Pozzo F, Ragusa D, Bulian P, Rossi D, Capelli G, Rossi FM, Niscola P, Buccisano F, Bomben R, Zucchetto A, Maurillo L, de Fabritiis P, Amadori S, Gaidano G, Gattei V, Del Poeta G.

Ann Hematol. 2014 Oct;93(10):1765-74. doi: 10.1007/s00277-014-2117-x. Epub 2014 Jun 13.

PMID:
24923451
39.

Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor.

Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I, Valenti V, Rossi D, Bonacorsi G, Zucchini P, Potenza L, Vallisa D, Gattei V, Del Poeta G, Forconi F, Gaidano G, Narni F, Luppi M, Marasca R.

PLoS One. 2014 Jun 5;9(6):e98818. doi: 10.1371/journal.pone.0098818. eCollection 2014.

40.

High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma.

Del Principe MI, Buccisano F, Cefalo M, Maurillo L, Di Caprio L, Di Piazza F, Sarlo C, De Angelis G, Irno Consalvo M, Fraboni D, De Santis G, Ditto C, Postorino M, Sconocchia G, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2014 Sep;93(9):1509-13. doi: 10.1007/s00277-014-2080-6. Epub 2014 Apr 22.

PMID:
24752416
41.

Pure erythroid leukemia in advanced breast cancer.

Niscola P, Tendas A, Minelli M, Perrotti A, de Fabritiis P, Del Poeta G.

Blood Res. 2014 Mar;49(1):69-72. doi: 10.5045/br.2014.49.1.69. Epub 2014 Mar 24. No abstract available.

42.

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia.

Bulian P, Shanafelt TD, Fegan C, Zucchetto A, Cro L, Nückel H, Baldini L, Kurtova AV, Ferrajoli A, Burger JA, Gaidano G, Del Poeta G, Pepper C, Rossi D, Gattei V.

J Clin Oncol. 2014 Mar 20;32(9):897-904. doi: 10.1200/JCO.2013.50.8515. Epub 2014 Feb 10.

43.

Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia.

Del Principe MI, Cefalo M, Buccisano F, Anemona L, Sarlo C, Di Caprio L, De Santis G, Giacobbi E, Maurillo L, Postorino M, Del Poeta G, Amadori S, Venditti A.

Ann Hematol. 2014 Sep;93(9):1611-2. doi: 10.1007/s00277-014-2010-7. Epub 2014 Jan 23. No abstract available.

PMID:
24452366
44.

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A.

Am J Hematol. 2014 May;89(5):480-6. doi: 10.1002/ajh.23668. Epub 2014 Feb 18.

45.

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

Pozzo F, Dal Bo M, Peragine N, Bomben R, Zucchetto A, Rossi F, Degan M, Rossi D, Chiarenza A, Grossi A, Di Raimondo F, Zaja F, Pozzato G, Secchiero P, Gaidano G, Del Poeta G, Zauli G, Fo À R, Guarini A, Gattei V.

J Hematol Oncol. 2013 Nov 5;6:83. doi: 10.1186/1756-8722-6-83.

46.

CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells.

Rossi FM, Zucchetto A, Tissino E, Dal Bo M, Bomben R, Caldana C, Pozzo F, Del Poeta G, Rossi D, Gaidano G, Gattei V.

Leukemia. 2014 Mar;28(3):705-8. doi: 10.1038/leu.2013.331. Epub 2013 Nov 8. No abstract available.

PMID:
24202404
47.

Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.

Del Principe MI, Buccisano F, Maurillo L, Venditti D, Cefalo M, Sarlo C, Di Caprio L, Di Veroli A, Nasso D, Ceresoli E, Postorino M, Di Piazza F, Colandrea G, Conti F, Del Poeta G, Amadori S, Venditti A.

Thromb Res. 2013 Nov;132(5):511-4. doi: 10.1016/j.thromres.2013.08.007. Epub 2013 Aug 16.

PMID:
24090605
48.

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.

Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D'Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V.

Blood. 2013 Nov 7;122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25.

PMID:
24068493
49.

Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab.

Niscola P, Ragusa D, Scaramucci L, Giovannini M, Piccioni D, Tendas A, Perrotti A, de Fabritiis P, Del Poeta G.

Ann Hematol. 2014 May;93(5):863-5. doi: 10.1007/s00277-013-1877-z. Epub 2013 Aug 16. No abstract available.

PMID:
23949377
50.

Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey.

D'Arena G, Laurenti L, Coscia M, Cortelezzi A, Chiarenza A, Pozzato G, Vigliotti ML, Nunziata G, Fragasso A, Villa MR, Grossi A, Selleri C, Deaglio S, La Sala A, Del Poeta G, Simeon V, Aliberti L, De Martino L, Giudice A, Musto P, De Feo V.

Leuk Lymphoma. 2014 Apr;55(4):841-7. doi: 10.3109/10428194.2013.803223. Epub 2013 Oct 17.

PMID:
23829282

Supplemental Content

Loading ...
Support Center